Dr.Nanci | Research design and Mixed Methods Research.
19 Jan, 2025
Controlled clinical trials are the highest level of clinical research and are very helpful in giving insight into the effectiveness of different interventions. Whether the intervention is a new drug, dietary supplement, or behavioral intervention, CCTs ensure that the results obtained are reliable and valid. Designing and conducting a controlled clinical trial involves several crucial steps, from defining the research question to data analysis and reporting. It lists the basic principles and guidelines necessary for designing and conducting controlled clinical trials, including illustrative examples and best practice recommendations from a variety of sources.
Study Design | Description | Advantages | Disadvantages |
Randomized Controlled Trial (RCT) | Participants are randomly assigned to intervention or control groups. | Best method for clinical trials. Controls bias effectively. | Expensive, time-consuming, ethical concerns in random assignment [4]. |
Crossover Trial | Participants receive both the treatment and placebo in a sequential manner. | Reduces variability by using the same participants. | Carryover effects, more complex analysis [5]. |
Blinded Trial | Participants or researchers are unaware of the assigned interventions. | Reduces bias from participants and researchers. | Can be difficult to blind for certain types of interventions (e.g., surgery). [6] |
Open-Label Trial | Both the participants and researchers are aware of the intervention. | Easier to implement, particularly for long-term studies. | Higher risk of bias, particularly in subjective outcome assessments [7]. |
Parallel Group Trial | Different groups are assigned different interventions and remain separate. | Simplifies analysis and allows for comparison of different treatments. | Requires larger sample sizes to achieve statistical power [8]. |
Factorial Design | Participants are randomly assigned to different combinations of interventions. | Allows for testing of multiple treatments simultaneously. | Complex to design and analyze, can be difficult to interpret interactions [9]. |
Non-inferiority Trial | Designed to demonstrate that a new treatment is not worse than an existing one. | Useful for comparing new drugs to existing ones when new treatments are cost-effective or less invasive. | Interpretation of "non-inferiority" can be complex and context dependent. |
Equivalence Trial | Aims to show that two treatments are equally effective. | Useful for establishing that a new treatment is as effective as a current standard. | Requires precise definitions of equivalence, regulatory challenges [10]. |
Multicenter Trial | Conducted across multiple locations to increase generalizability. | Increases sample size, improves external validity. | Coordination and data consistency across sites can be challenging [11]. |
The research question acts as the cornerstone of a clinical trial, framing the study’s purpose and guiding all subsequent decisions. A well-defined research question identifies the population, intervention, comparison, and outcome (PICO). Here’s an example:
This question clearly defines:
The hypothesis is a specific, testable, and measurable statement derived from the research question. It should be formulated using the SMART criteria (Specific, Measurable, Achievable, Relevant, Time-bound).
This hypothesis is:
With the research question and hypothesis defined, the study can be designed effectively:
This structured approach ensures that the research is focused, feasible, and yields valid, actionable results.
In a controlled clinical trial, randomization removes bias to ensure the output of results validity. RCTs are considered the best possible design for a research study, as they most significantly limit confounding effects by distributing participants randomly through various groups of treatment under investigation.
Randomization plays a crucial role in making the confounding variables distributed evenly across groups, enhancing generalizability. In the case of a drug that is tested for reducing cholesterol, randomization in such a trial ensures that the factors of age, sex, and pre-existing conditions do not disproportionately impact the result between the treatment and control groups [3].
The design also typically includes a control group, which is given either a placebo or the current standard of care. This will enable the researcher to compare the effect of the intervention against a baseline, hence giving a clear assessment of its efficacy [2]. A control group plays an important role in isolating the effects of the intervention from other variables, such as the placebo effect or natural disease progression.
A clear definition of inclusion and exclusion criteria is a vital step in participant selection. Inclusion criteria would include those traits for qualification into the study; those might include age, gender, health condition, or any of several levels of disease. Exclusion criteria are applied where participants are disqualified from featuring in the trials. They include health conditions, pregnancy, or medication use, among other things that could influence the studies.
For instance, in a study of an intervention diet for diabetes, subjects might be required to have type 2 diabetes and fall within a particular age group. Exclusion criteria would include pregnant women or patients with kidney disease because these conditions may affect the outcome or put the patients at risk.
Moreover, clearly defining these criteria determines the homogeneity of study samples and reduces variability, making the results more interpretable [3].
Sample size calculation is a critical component of trial design to ensure that the study has sufficient power to detect a meaningful effect while minimizing errors:
A clinical trial is designed to evaluate whether a new dietary supplement reduces systolic blood pressure compared to a placebo in adults with hypertension.
For a two-sided test with equal group sizes:
Where:
Substituting Values
𝑛 = 2(1.96+0.84)2(10)2/52
𝑛 = 2 × 7.84 × 100 / 25
= 1568 / 25
= 62.72
The required sample size is approximately 63 participants per group. To account for dropouts, a buffer of 10-20% can be added, bringing the total to around 70-75 participants per group.
This calculation ensures:
By systematically calculating sample size, researchers can design robust and reliable trials.
Calculating a sample size is one of the essential steps in trial design. A well-powered study minimizes the chance of Type I (false positives) and Type II errors (false negatives). A Type I error is said to be committed when a study claims to find an effect at some particular significance level, but there is no real effect. Type II error takes place when the study fails to detect a true effect.
Sample size should be calculated based on an anticipated effect size, with a statistical power generally set at 80-90%, and the level of significance is generally set to 0.05 [1]. For example, assuming the difference to be expected in blood pressure reduction due to a particular dietary supplement is modest, more participants may be needed in the sample size to attain high confidence for detecting an effect.
Sample size calculation is one of the important steps in the design of a trial. A well-powered study minimizes the chances of Type I and Type II errors. A Type I error occurs when a study finds a significant effect that is not present, whereas a Type II error occurs when the study fails to detect an existing effect.
Among its techniques to prevent bias are blinding and allocation concealment. Blinding includes keeping the participants and/or investigators unaware of the nature of the group the patient is assigned to (that one must go for treatment or not) in order to minimize treatment administration bias and measurement biases.
In Double-blind trials neither the participants nor the investigators are aware of which group they are in. In some instances, however, single blinding, in which only the participants are unaware, may be appropriate.
Data collection in the controlled clinical trial must always be systematic and standardized to ensure the reliability of the results. In this regard, the validated measurement tools and instruments should be used to capture the desired outcomes accurately. For nutrition trials, for example, changes in weight, BMI, blood pressure, or blood lipid levels are some of the outcome measures.
In addition, in controlled trials, the continuous monitoring of participant safety and data integrity is very important. Data safety monitoring boards (DSMBs) are often used to monitor the progress of the trial and ensure participant safety while resolving any emerging issues. This is particularly important in high-risk intervention trials, such as new medications or interventions in vulnerable populations.
The statistical analysis is a critical component of the trial design and is utilized in the interpretation of the collected data. The selection of the statistical method depends on the study design, the data distribution, and the hypotheses being tested. For instance, when comparing the efficacy of two interventions, tests like t-tests or ANOVA can be applied.
Using appropriate statistical models helps in the evaluation of treatment effects and any possible confounders. Intention-to-treat (ITT) analysis is also an essential requirement, whereby all participants who were randomized would be included in the analysis irrespective of whether they completed the study or followed the treatment regimen. It thus reduces bias and would result in a more accurate representation of real-life settings.
Ethical considerations play a critical role in the design and conduct of clinical trials. The informed consent to be obtained, participant confidentiality, and minimizing harm all are part of ethical research. An institutional review board (IRB) often requires ethical approval before initiating the trial.
In this case, the last requirement is clear reporting of the results of a clinical trial without manipulation. The clear reporting and completeness, including even following the CONSORT statement (Consolidated Standards of Reporting Trials), assist with the validity and reproducibility of the findings. The researchers should also show transparency in the presence of conflict of interest and funding.
Table 2: Controlled Clinical trials in nutrition (Feeding Trial) [2]
Type | Setting | Example | Outcomes |
---|---|---|---|
Fully domiciled | Participants live entirely at the research facility (e.g., metabolic chambers or inpatient centers). | Comparing carbohydrate-restricted and fat-restricted diets on body weight. | Demonstrated distinct impacts of macronutrient restrictions on body weight outcomes. |
Investigating how ultra-processed foods influence energy consumption. | Highlighted increased caloric intake associated with ultra-processed food consumption. | ||
Partially domiciled | Participants consume meals at the facility but spend most of their time at home. | Evaluating the effect of time-restricted eating on weight changes. | Indicated a correlation between restricted eating windows and weight management. |
Assessing the impact of the Chinese Heart-Healthy Diet on blood pressure. | Showed significant reductions in blood pressure following dietary intervention. | ||
Nondomiciled | Meals are delivered to participants for consumption at their homes. | Examining the DASH diet's effect on blood pressure. | Demonstrated effective blood pressure reduction linked to the DASH diet. |
Studying the Dietary Guidelines for Americans-based diet on cardiometabolic health. | Indicated improved cardiometabolic indices in participants adhering to the dietary guidelines. |
A controlled clinical study must be carefully planned and carried out, taking ethical considerations into account throughout the process. Using the best practices in designing, randomizing, data gathering, and analysis by a researcher can ensure the relevance, reliability, and reproducibility of trials’ results. A good clinical trial will contribute to advances in medical and nutritional science in bringing better care for the patients and improved public health.